In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The significance of diabetes mellitus on left ventricular function, heart rate variability and frequency of supraventricular arrhythmias in patients after myocardial infarction

Session Poster Session 2

Speaker Associate Professor Viktor Stoickov

Congress : Heart Failure 2018

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart
  • Session type : Poster Session
  • FP Number : P1243

Authors : V Stoickov (Nis,RS), M Deljanin Ilic (Nis,RS), M Stoickov (Niska Banja,RS), S Saric (Niska Banja,RS), S Andonov (Niska Banja,RS), D Marinkovic (Niska Banja,RS), I Tasic (Nis,RS), D Simonovic (Niska Banja,RS), S Mitic (Niska Banja,RS)

15 views

Authors:
V Stoickov1 , M Deljanin Ilic1 , M Stoickov2 , S Saric2 , S Andonov2 , D Marinkovic2 , I Tasic1 , D Simonovic2 , S Mitic2 , 1University of Nis, Medical Faculty, Institute of Cardiology Niska Banja - Nis - Serbia , 2Institute of Cardiology - Niska Banja - Serbia ,

Citation:

Background/Introduction: Coronary patients with diabetes are at high risk of cardiovascular events. Coronary disease in diabetic patients has speed up, progressive course because of the synergic work of hyperglycemia and other risk factors of the coronary disease, as well as dyslipidemia, hypertension, obesity and smoking too.

Purpose: The aim of this study was to establish the significance of diabetes mellitus on left ventricular function, heart rate variability and freqency of supraventricular arrhythmias in patients after myocardial infarction (MI). 

Methods: We studied 337 patients after MI, in the sinus rhythm without AV blocks or branch blocks. 112 patients were with diabetes mellitus, and 225 were without diabetes. Patients were of similar age, site of infarction and baseline stress test duration. In all subjects 24-hour ECG recording and echocardiographic examination were performed. From the holter record, the analysis of the heart rate variability was performed by software. Four parameters of  the time domain heart rate variability were assessed: SDNN, SDANN, RMS-SD and NN>50 ms. 

Results: Patients with diabetes had a higher percentage of frequent (>10 supraventricular premature complexes / hour) and complex supraventricular arrhythmias (38.5 vs 19.2%, p<0.001) and supraventricular tachycardias (28.8 vs 6.1%, p<0.001) than in those without diabetes. Patients with diabetes also had significantly lower values of followed parameters of the heart rate variability (78.6 ± 20.1 vs 102.1 ± 28.7 ms, p<0.001 for SDNN; 66.9 ± 18.7 vs 85.6 ± 29.7 ms, p<0.001 for SDANN; 24.7 ± 10.6 vs 35.4 ± 14.9 ms, p<0.001 for RMS-SD and 5.8 ± 5.6 vs 12.2 ± 10.3, p<0.001 for NN>50ms) in comparison to those without diabetes. Patients with diabetes also had significantly lower values of left ventricular ejection fraction (45.0 ± 9.6 vs 54.3 ± 13.8 %, p<0.001) and significantly higher values of left ventricular end-systolic diameter (39.5 ± 5.6 vs 35.6 ± 6.8 mm, p<0.001), left ventricular end-diastolic diameter (55.8 ± 5.4 vs 53.1 ± 5.6 mm, p<0.001) and left atrium (43.2 ± 5.6 vs 39.2 ± 4.7 mm, p<0.001), in comparison to those without diabetes. 

Conclusions: The study showed that in patients after MI, diabetes mellitus have a  significant impact on left ventricular function, heart rate variability and supraventricular arrhythmias. The reason for that is more severe degree of the left ventricle dysfunction, diabetic neuropathy and greater inhomogeneous repolarization of myocardium.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are